Search Results
Your search for ,WhO matches 21068 pages
Showing 4451 - 4500Sequencing Therapies May Improve Overall Survival in Metastatic Pancreatic Cancer
In the first-line treatment of metastatic pancreatic cancer, the sequencing of nab-paclitaxel plus gemcitabine with FOLFOX (fluorouracil, leucovorin, oxaliplatin) resulted in a significant improvement in overall survival at 12 months and in all other efficacy endpoints as compared with the standard ...
Snapshots of Studies of Interest Presented at ASCO 2022
The 2022 ASCO Annual Meeting was filled with important science, engaging data, and several practice-changing abstracts, many of which have been covered in detail on other pages or in earlier issues of The ASCO Post. There were numerous high-impact studies and attendees, whether present at the...
Impact of the Dobbs v Jackson Women’s Health Organization Ruling on Patients With Cancer
As a nonpartisan organization, the American Cancer Society has an overarching goal to improve the lives of patients with cancer and their families. We believe all individuals should have an equitable opportunity to prevent, find, detect, and survive cancer, irrespective of geography. The June 24...
Is Science Getting Closer to Preventing Multiple Myeloma?
About 3 years ago, researchers from Dana-Farber Cancer Institute launched PROMISE (Predicting Progression of Developing Myeloma in a High-Risk Screen Population; ClinicalTrials.gov identifier NCT03689595), a large, ambitious screening study to identify individuals at high risk of developing...
Expert Point of View: Alexey V. Danilov, MD, PhD
According to Alexey V. Danilov, MD, PhD, Professor and Co-Director, Toni Stephenson Lymphoma Center, City of Hope, diffuse large B-cell lymphoma (DLBCL) refractory to chemotherapy represents an unmet medical need, with data from the SCHOLAR-1 study demonstrating a median overall survival of...
Epcoritamab Under Study in Difficult-to-Treat Large B-Cell Lymphoma
Subcutaneous epcoritamab, a bispecific antibody, has demonstrated deep and durable responses in a large expansion cohort of patients with relapsed or refractory large B-cell lymphoma (LBCL), according to late-breaking data presented during the European Hematology Association (EHA) 2022 Congress in...
Real-World Evidence Confirms Survival Benefit of Durvalumab in Locally Advanced Non–Small Cell Lung Cancer
In locally advanced non–small cell lung cancer (NSCLC), immunotherapy consolidation with the PD-L1 inhibitor durvalumab improved overall survival in the PACIFIC trial,1 thus leading to its use after chemoradiotherapy as a standard of care. Real-world evidence of durvalumab’s effect on overall and...
PREMMplus Tool May Assist in Identifying People Likely to Benefit From Multigene Hereditary Cancer Risk Assessment
An online tool developed by researchers and physicians at Dana-Farber Cancer Institute may accurately and rapidly identify people who should undergo testing for inherited genetic changes that raise the risk of developing certain cancers, according to findings reported by Yurgelun et al in the...
Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma
In a study reported in the Journal of Clinical Oncology, de Vries et al developed risk models for predicting the development of coronary heart disease and heart failure in patients treated for Hodgkin lymphoma. Study Details The prediction models were developed in a Dutch cohort of 1,433 5-year...
Is Advance Care Planning of Any Value?
An article in The New York Times earlier this year crystallized the dilemma facing health-care providers when they are presented with a patient in a life-threatening situation: Should they rely on advance care directives written years prior to the current medical situation to accurately determine...
Does Exposure to 'Forever Chemical' Elevate Risk of Developing Hepatocellular Carcinoma?
Exposure to a synthetic chemical found widely in the environment may be linked to the development of nonviral hepatocellular carcinoma, according to a new study published by Goodrich et al in JHEP Reports. The chemical—called perfluorooctane sulfate, or PFOS—is one of a class of man-made chemicals...
T-DXd Shows High Intracranial Response Rate in Patients With Active Brain Metastases From HER2-Positive Breast Cancer
In the investigator-initiated, prospective, open-label, single-arm phase II TUXEDO-1 study conducted among patients with newly diagnosed or progressive brain metastases from HER2-positive breast cancer, the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) yielded responses according...
Low-Dose Decitabine and Azacitidine in Lower-Risk MDS
As reported in NEJM Evidence by Sasaki et al, extended follow-up of a phase II trial showed good outcomes with low doses of the hypomethylating agents decitabine and azacitidine in previously untreated patients with lower-risk myelodysplastic syndromes (MDS). Study Details The study included 113...
FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients With Beta-Thalassemia Who Require Regular Blood Transfusions
On August 17, the U.S. Food and Drug Administration (FDA) approved betibeglogene autotemcel (Zynteglo), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. “[This] approval is an important...
A Surgical Oncologist From Afghanistan Discusses the Challenges of Delivering Cancer Care in a War-Torn Nation
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Ahmad Bashir Barekzai, MD, FACS, Consultant Surgical Oncologist at Ali Abad Teaching Hospital, an affiliated hospital to Kabul University of Medical Science, Kabul,...
GnRH Agonist Therapy for Prostate Cancer and Cardiovascular Disease Risk in Men With Type 2 Diabetes
In a Swedish population-based cohort study reported in JAMA Network Open, Lin et al found that men with type 2 diabetes receiving gonadotropin-releasing hormone (GnRH) agonists for prostate cancer were more likely to have an increased risk for developing cardiovascular disease compared with those...
Relationship Between Polypharmacy and Frailty Among Older Adults With Blood Cancers
A new study published by Hshieh et al in JNCCN–Journal of the National Comprehensive Cancer Network suggests a new way for hematologic oncologists to protect older patients from the risks of medication interactions. As part of the Older Adult Hematologic Malignancies Program, gerontology...
Sugemalimab Found to Be a Safe and Effective Consolidation Therapy for Patients With Unresectable Stage III NSCLC
The human monoclonal antibody sugemalimab is a safe and effective consolidation therapy for patients with unresectable stage III non–small cell lung cancer (NSCLC) without disease progression after either concurrent chemoradiotherapy (cCRT) or sequential chemoradiotherapy (sCRT), according to...
Higher Doses of CAR T-Cell Therapy May Improve Survival for Young Patients With B-Cell ALL
Young people with B-cell acute lymphoblastic leukemia (ALL) who received doses of tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy, at the higher end of the approved dosing range had significantly better survival rates at 1 year compared with those who received lower doses within...
Sexual Dysfunction Is Prevalent Among Women With Lung Cancer
Sexual dysfunction is highly prevalent in women with lung cancer, with most participants in a survey reporting little to no interest in sexual activity, according to research led by Narjust Florez (Duma), MD, presented at the International Association for the Study of Lung Cancer (IASLC) World...
Study Investigates Incidence, Timing, and Survival of Patients With Second Primary Lung Cancer
Using data from the National Lung Screening Trial (NLST), researchers found that the incidence of second primary lung cancer was approximately 4% among the entire cohort of patients with lung cancer and was as high as 8% among patients undergoing surgery for stage IA disease. The research was...
Perspective Article Explores Implications of Supreme Court Abortion Ruling on Pregnant Women With Cancer
The repercussions of overturning Roe v Wade—and the failure of the Supreme Court to provide any guidance on exceptions related to the life and health of the mother—are potentially catastrophic for a subset of women who face a life-threating diagnosis of pregnancy-associated cancers. In a...
Locoregional Recurrence With Predefined Risk-Based De-escalation of Radiotherapy After Primary Chemotherapy in cT1–2N1 Breast Cancer
As reported in The Lancet Oncology by de Wild et al, 5-year follow-up from a Dutch prospective registry study (RAPCHEM, BOOG 2010-03) showed low rates of locoregional recurrence with de-escalation of adjuvant radiotherapy according to predefined risk levels in women receiving primary chemotherapy...
INTRIGUE Trial: Second-Line Ripretinib vs Sunitinib in Advanced GIST
As reported in the Journal of Clinical Oncology by Bauer et al, the phase III INTRIGUE trial showed no significant progression-free survival benefit with second-line ripretinib vs sunitinib in imatinib-pretreated patients with gastrointestinal stromal tumor (GIST), including among patients with KIT ...
Durvalumab Plus Concurrent Radiotherapy in Unresectable Locally Advanced NSCLC: DOLPHIN Study
Researchers from Japan recently reported that the first phase II study to evaluate the efficacy and safety of durvalumab and concurrent curative radiation therapy for PD-L1–positive unresectable locally advanced non–small cell lung cancer (NSCLC) without chemotherapy met its primary endpoint with...
Does Daily Insulin Dose Affect Cancer Risk in Patients With Type 1 Diabetes?
In an analysis reported in JAMA Oncology, Zhong and Mao found that a higher daily insulin dose was associated with an increased risk of cancer diagnosis in patients with type 1 diabetes. Study Details The analysis used data from the Diabetes Control and Complications Trial (DCCT) and the...
Models to Assess Impact of Centralization of Specialist Cancer Services in England
In a study reported in The Lancet Oncology, Aggarwal et al identified the impact of several models of centralization of specialist cancer services in England, using rectal cancer surgery as an example. As stated by the investigators, “Centralization of specialist cancer services is occurring in...
FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for HER2-Mutant NSCLC
On August 11, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for adult patients with unresectable or metastatic non–small cell lung cancer (NSCLC) whose tumors have activating HER2 mutations, as detected by an...
Research Suggests Air Pollution Be Included as Risk Factor for Nonsmoking Patients With Lung Cancer
Researchers from Vancouver, British Columbia examined the effect of duration of past exposure to air pollution with lung cancer diagnosis in new research presented by Myers et al at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2022 (Abstract...
Disparities in the Diagnosis of Lung Cancer Among Younger vs Older Adults
Younger patients with lung cancer are significantly more likely than older patients to be diagnosed with later stages of disease, illustrating the need to develop strategies to increase the early detection of lung cancer among younger patients who are currently ineligible for lung cancer screening. ...
FDA Approves Ventana MMR RxDx Panel to Identify Patients With dMMR Solid Tumors and pMMR Endometrial Cancer Eligible for Treatment With Pembrolizumab
On August 11, Roche announced the U.S. Food and Drug Administration (FDA) approval of a label expansion for the Ventana MMR RxDx Panel. The Ventana MMR RxDx Panel is the first immunohistochemistry (IHC) companion diagnostic test to aid in identifying patients whose solid tumors are deficient in DNA ...
PSA Screening and Prostate Cancer Mortality Among Black and White Veterans
In a study reported in JAMA Oncology, Sherer et al found that prostate-specific antigen (PSA) screening was associated with reduced prostate cancer mortality among both non-Hispanic Black and non-Hispanic White U.S. veterans who developed prostate cancer. Annual vs some screening was associated...
Evaluating Strategies for Treating Pediatric Metastatic Rhabdomyosarcoma
In a report in the Journal of Clinical Oncology, Schoot et al provided findings from the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 and pooled findings of MTS 2008 with those of the concurrent BERNIE study, both of which evaluated strategies for the treatment of pediatric...
Study Finds AYA Leukemia Survivors Have Higher 10-Year Mortality Rates Than the General Population
Although considered a rare occurrence in adolescents and young adults (AYAs), aged 15 to 39 years, the incidence of cancer in this age group has been increasing by approximately 30% since the 1970s. This year, it is estimated that nearly 90,000 new cases of cancer will be diagnosed in this...
Thriving After a Diagnosis of Stage II Anal Cancer
About 7 years ago, I had emergency hernia surgery and soon after began experiencing severe constipation and abdominal bloating. I had started to have minor symptoms leading up to the surgery, but now the pain and exhaustion of trying to have a bowel movement became unbearable. I met with a...
Dana-Farber’s Irene Ghobrial, MD, Selected as William Dameshek Prize Winner
Irene Ghobrial, MD, Director of the Clinical Investigator Research Program at Dana-Farber Cancer Institute, Boston, has received the William Dameshek Prize. This award is given annually by the American Society of Hematology (ASH) to an individual younger than age 50 who has made outstanding...
Jaye Gardiner, PhD, Receives the 2022 Eddie Méndez Award Honoring Underrepresented Scientists
Jaye Gardiner, PhD, a postdoctoral fellow at Fox Chase Cancer Center, Philadelphia, is among 10 recipients of the 2022 Dr. Eddie Méndez Award. This honor recognizes underrepresented postdoctoral researchers across the United States who have demonstrated research expertise in cancer, infectious...
Radiologist Claudia Henschke, PhD, MD, of Icahn School of Medicine, Receives the 37th Annual Alton Ochsner Award
Ochsner Health has announced the recipient of the 37th Annual Alton Ochsner Award Relating Smoking and Disease: Claudia Henschke, PhD, MD. She is Director, Early Lung and Cardiac Action Program (ELCAP) and Professor of Radiology at the Icahn School of Medicine at Mount Sinai, New York. This...
An Oncology Nurse Becomes a Cancer Survivor
In 2016, Theresa Brown, RN, wrote The Shift: One Nurse, Twelve Hours, Four Patients’ Lives, a vivid real-time description of an oncology nurse’s standard 12-hour shift on a hospital cancer ward. It was an excellent book, which was reviewed on these pages and highly recommended for readers of The...
Robert Uzzo, MD, MBA, FACS, Appointed President and CEO of Fox Chase Cancer Center
Robert Uzzo, MD, MBA, FACS, has been named President and Chief Executive Officer (CEO) of Fox Chase Cancer Center, Philadelphia. In addition, Dr. Uzzo will assume the roles of Executive Vice President, Cancer Services for Temple University Health System, and Senior Associate Dean, Clinical Cancer...
His Grandmother’s Death Inspires a Career in Oncology for Manmeet S. Ahluwalia, MD, MBA
In this installment of Living a Full Life, Guest Editor Jame Abraham, MD, spoke with Manmeet S. Ahluwalia, MD, MBA, Deputy Director, Chief Scientific Officer, and Chief of Solid Tumor Medical Oncology at Miami Cancer Institute, where his research focuses on the development of new therapies for...
How ASCO and ACCC Aim to Increase Diversity in Clinical Trials and Close the Equity Gap in Cancer Care
Research shows that although 15% of Black individuals and 13% of Hispanic individuals have cancer in the United States, only between 4% and 6% of clinical trial participants are Black and between 3% and 6% are Hispanic.1-3 To improve these statistics, in 2020, ASCO and the Association of Community...
Selwyn M. Vickers, MD, FACS, Named President and CEO of Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSK) recently announced that Selwyn M. Vickers, MD, FACS, a pancreatic cancer surgeon and researcher, a pioneer in cancer health disparities research, and an academic medical leader, has been selected to serve as its next President and Chief Executive...
Initiatives by Professional Oncology Organizations Focus on Improving Equitable Cancer Care
At the 2022 Summit on Cancer Health Disparities in Seattle, leaders from five of the leading professional societies in cancer discussed their respective organizations’ current initiatives toward improving cancer health disparities.1 Representatives from ASCO, the American Society for Clinical...
Increased Utilization of SBRT Has Decreased Treatment Disparities for Early-Stage NSCLC
The use of stereotactic body radiotherapy (SBRT) for patients with non–small cell lung cancer (NSCLC) can reduce treatment disparities between White and Black patients, according to research presented by Ganesh et al at the International Association for the Study of Lung Cancer (IASLC) World...
Study Finds Adding Tremelimumab and Durvalumab to Chemotherapy Improves Overall Survival in Metastatic NSCLC Regardless of KRAS/STK11/KEAP1 Mutations
Patients with metastatic non–small cell lung cancer (NSCLC) who received a combined therapy of tremelimumab, durvalumab, and chemotherapy experienced longer overall survival compared with those who received chemotherapy alone, regardless of STK11, KEAP1, or KRAS mutational status. These findings...
Long-Term Regional Disease Control With Sentinel Lymph Node Biopsy in Patients With Melanoma
In an analysis of the Multicenter Selective Lymphadenectomy Trial II reported in JAMA Surgery, Crystal et al found that patients with melanoma with sentinel lymph node (SLN) metastasis who were randomly assigned to observation vs completion lymph node dissection (CLND) following SLN biopsy...
ASCO and WHO to Collaborate on Quality Indicators for Cancer Facilities
In a collaboration announced on June 4, ASCO will work with the World Health Organization (WHO) to measure and improve the quality of cancer care internationally. The goal is to achieve health-related targets of the U.N. Sustainable Development Goals and WHO Global Action Plan on Non-Communicable...
ASCO Releases First Comprehensive Evidence-Based Guidelines for Metastatic Clear Cell Renal Cell Carcinoma
ASCO has released the first comprehensive set of guidelines for the management of metastatic clear cell renal cell carcinoma (RCC).1 The guidelines are subdivided into six main sections: diagnosis, the role of cytoreductive nephrectomy, first-line systemic treatment, second- or later-line systemic...
ASCO Endorses New ASTRO Guideline on the Use of Radiation Treatment of Metastatic Brain Cancer
ASCO has endorsed the recommendations put forth in a new guideline, developed by the American Society for Radiation Oncology (ASTRO), on the use of radiation therapy for the management of brain metastases.1,2 Although ASTRO—in conjunction with ASCO and the Society for Neuro-Oncology (SNO)—recently...
